Sabitlenmiş Tweet
The story continues at a new index, nobrainerbio.substack.com/p/article-index.
Current articles as of this writing:
1 - Fix the Tap, Don’t Mop the Flood nobrainerbio.substack.com/p/fix-the-tap-…
The case for InflaRx — and why one forgotten molecule could be the most important anti-inflammatory asset in biotech
An introduction to the C5a signaling pathway, vilobelimab, and INF904 — and why controlling inflammation at its upstream source changes everything.
2 - The Killer Nobody Names nobrainerbio.substack.com/p/the-killer-n…
Why the modern world is killing us from the inside out — and what the leading causes of death are hiding
Three in five deaths globally trace back to chronic inflammation — a public health crisis hiding in plain sight behind named diseases.
3 - HS - The Disease That Hides in Plain Sight nobrainerbio.substack.com/p/the-disease-…
Seven years to diagnosis. Treatments that miss the point. And a molecule that could change both.
Hidradenitis suppurativa — a neutrophil-driven inflammatory disease of the skin — and why every approved treatment targets downstream of the real problem.
4 - PG - The Wound That Shouldn’t Exist nobrainerbio.substack.com/p/the-wound-th…
Pyoderma gangrenosum destroys tissue for no reason medicine can explain — and for forty years, the only upstream answer has been ignored.
Pyoderma gangrenosum, the role of C5a and NETosis in its destruction, and why a flawed trial endpoint — not a flawed drug — derailed the first targeted therapy.
5 - AAV - Steroid-Sparing Isn’t Steroid-Free nobrainerbio.substack.com/p/steroid-spar…
Reducing steroids was a milestone. Eliminating steroids is the goal. In AAV, no approved drug has crossed that line.
ANCA-associated vasculitis, the limits of avacopan, and the pharmacological case for INF904 as the first drug capable of achieving true steroid-free remission.
6 - ARDS - The Body Sets Itself on Fire nobrainerbio.substack.com/p/ards-the-bod…
A drug approved in Europe. An ICU full of dying patients. A bureaucratic wall between the two.
Acute respiratory distress syndrome, the neutrophil-driven lung destruction at its core, and why a fully approved drug is sitting unused while patients die.
7 - DKD - The Kidney Nobody’s Looking At nobrainerbio.substack.com/p/the-kidney-n…
Diabetic kidney disease is the leading cause of kidney failure worldwide. The standard of care slows it. It does not stop it...yet.
Diabetic kidney disease, the C5a-C5aR1 signaling that drives its progression, and why INF904 may offer the first mechanism capable of altering its course.
8 - IgAN - The Young Kidney Claimed By An Ancient Protein nobrainerbio.substack.com/p/8-igan-the-y…
Complement inhibition confirmed, a drug approved, still a flood.
IgA nephropathy, the complement activation that drives it, and why blocking complement upstream may be the answer a newly approved drug class is still only partially providing.
9 - LN - When the Body Attacks Itself nobrainerbio.substack.com/p/9-ln-when-th…
Three drugs approved. Six in ten patients still failing. The upstream trigger nobody has touched.
Lupus nephritis, the classical complement pathway that fires with every flare, and why the molecule initiating each attack has never been targeted in a clinical trial in this disease.
10 - MN - When the Immune System Opens the Floodgates nobrainerbio.substack.com/p/10-mn-when-t…
One million microscopic filters under autoimmune attack. A complement cascade the field has been misreading for fifty years. And an upstream target nobody has tried.
Primary membranous nephropathy, the autoimmune trigger that destroys the kidney’s final filtration barrier, and why no complement inhibitor has ever been tested in the most complement-dependent kidney disease in nephrology.
Indexes of the past: x.com/3in5saved/stat…
English
